

Haemonetics Corp. (HAE)

NYSE; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000313143

Haemonetics Corp. HAE; healthcare	
Grade	C A B C D E middle fifth of 371 graded peers percentile 51.9; sampling error 2.5 points; lower is stronger
Rank	193 of 371
Profitability	C percentile 49.2
Solvency	D percentile 68.8
Growth and financing	B percentile 28.0
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$2.4B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	11 of 14
Graded from	filings received through May 20, 2026 142 days before the rescans; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$119.53 2026-10-08; market equity \$5.4B
Price used in grade	None



C, the tortoise

middle fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: C/D from Mar 21, 2025, D from May 21, 2025, D/E from Mar 21, 2026, C from M

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received May 20, 2026

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms "we," "us," "our,"

"Haemonetics" and the "Company" mean Haemonetics Corporation.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 49.2						
Gross profitability		32.9%	32.2%	44.5	372	2026-03-28
Return on invested capital		6.7%	9.3%	56.2	74	2026-03-28
Accruals ratio		(8.1%)	(6.6%)	47.9	811	2026-03-28
Gross margin stability, five years		2.8 pts	2.8 pts	48.3	243	2026-03-28
Solvency, sleeve percentile 68.8						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-27 one or more required annual facts are missing interest expense must exceed \$100,000
Altman Z double-prime		not computable	(0.31)			
Net debt to EBITDA		4.56x	1.82x	81.1	75	2026-03-28
Interest coverage		not computable	(4.51x)			
Current ratio		2.95x	2.96x	56.6	839	2026-03-28
Growth and financing, sleeve percentile 28.0						
Revenue growth, three-year compound		4.5%	10.0%	61.4	415	2026-03-28
Free cash flow growth, three-year compound		47.2%	10.9%	14.7	96	2026-03-28
Reinvestment rate		140.2%	37.1%	24.3	104	2026-03-28
Asset growth, three years		7.4%	2.1%	36.3	704	2026-03-28
Net share issuance, one year		(5.4%)	2.5%	3.2	634	2026-05-15

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
188	Neuroone Medical Technologies Corp. (NMTC)	50.5	C	short runway, fortress balance sheet
189	RadNet, Inc. (RDNT)	50.8	C	
190	Schrodinger, Inc. (SDGR)	51.1	C	
191	Zai Lab Ltd. (ZLAB)	51.4	C	

192	Recursion Pharmaceuticals, Inc. (RXXR)	51.6	C	dilution, fortress balance sheet
193	Haemonetics Corp. (HAE) <	51.9	C	
194	Solventum Corp. (SOLV)	52.2	C	
195	Aveanna Healthcare Holdings, Inc. (AVAH)	52.4	C	
196	Nexgel, Inc. (NXGL)	52.8	C	late filer
197	Nexgel, Inc. (NXGLW)	52.8	C	late filer
198	Perrigo Co. plc (PRGO)	53.2	C	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	111.5%	8.0%	90
Distance from 52-week high	0.0%	(31.4%)	98
EBIT to enterprise value	2.4%	(1.5%)	63
Free cash flow yield	4.8%	(1.0%)	80
Book value to price	0.15	0.28	35
Sales to price	0.25	0.31	44
Composite equity issuance, five years	(11.3%)	20.3%	14
Relative strength against the sector, log excess return	0.54	(0.14)	90

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2026-03-28	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$223.4M
Operating cash flow, four quarters	\$328.1M
Months of runway	not finite
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$60.9M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$787.6M	2026-03-28	2026-05-20	10-K	0000313143-26-000050
2	assets	us-gaap:Assets	\$2.4B	2026-03-28	2026-05-20	10-K	0000313143-26-000050
3	operating income	us-gaap:OperatingIncomeLoss	\$156.7M	2026-03-28	2026-05-20	10-K	0000313143-26-000050
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordMeasOrDiscont	\$118.0M	2026-03-28	2026-05-20	10-K	0000313143-26-000050
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$30.7M	2026-03-28	2026-05-20	10-K	0000313143-26-000050
6	total debt	us-gaap:LongTermDebt	\$1.2B	2026-03-28	2026-05-20	10-K	0000313143-26-000050
7	book equity	us-gaap:StockholdersEquity	\$796.3M	2026-03-28	2026-05-20	10-K	0000313143-26-000050
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$245.4M	2026-03-28	2026-05-20	10-K	0000313143-26-000050
9	total debt	us-gaap:LongTermDebt	\$1.2B	2025-03-29	2025-05-21	10-K	0000313143-25-000025
10	book equity	us-gaap:StockholdersEquity	\$820.8M	2025-03-29	2026-05-20	10-K	0000313143-26-000050
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$306.8M	2025-03-29	2026-05-20	10-K	0000313143-26-000050
12	net income	us-gaap:NetIncomeLoss	\$97.3M	2026-03-28	2026-05-20	10-K	0000313143-26-000050

13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$293.2M	2026-03-28	2026-05-20	10-K	0000313143-26-000050
14	assets	us-gaap:Assets	\$2.5B	2025-03-29	2026-05-20	10-K	0000313143-26-000050
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.3B	2026-03-28	2026-05-20	10-K	0000313143-26-000050
16	gross profit	us-gaap:GrossProfit	\$749.0M	2025-03-29	2026-05-20	10-K	0000313143-26-000050
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.4B	2025-03-29	2026-05-20	10-K	0000313143-26-000050
18	gross profit	us-gaap:GrossProfit	\$691.5M	2024-03-30	2026-05-20	10-K	0000313143-26-000050
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.3B	2024-03-30	2026-05-20	10-K	0000313143-26-000050
20	gross profit	us-gaap:GrossProfit	\$615.1M	2023-04-01	2025-05-21	10-K	0000313143-25-000025
21	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$1.2B	2023-04-01	2025-05-21	10-K	0000313143-25-000025
22	gross profit	us-gaap:GrossProfit	\$505.5M	2022-04-02	2024-05-20	10-K	0000313143-24-000020
23	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$993.2M	2022-04-02	2024-05-20	10-K	0000313143-24-000020
24	depreciation amortization	us-gaap:Depreciation	\$61.2M	2026-03-28	2026-05-20	10-K	0000313143-26-000050
25	operating income	us-gaap:OperatingIncomeLoss	\$110.5M	2011-04-02	2013-05-20	10-K	0000313143-13-000085
26	interest expense	us-gaap:InterestExpense	\$6,000	2011-04-02	2011-05-26	10-K	0000950123-11-054481
27	current assets	us-gaap:AssetsCurrent	\$834.9M	2026-03-28	2026-05-20	10-K	0000313143-26-000050
28	current liabilities	us-gaap:LiabilitiesCurrent	\$282.6M	2026-03-28	2026-05-20	10-K	0000313143-26-000050
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$32.8M	2026-03-28	2026-05-20	10-K	0000313143-26-000050
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$181.7M	2025-03-29	2026-05-20	10-K	0000313143-26-000050
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$39.3M	2025-03-29	2026-05-20	10-K	0000313143-26-000050
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$181.8M	2024-03-30	2026-05-20	10-K	0000313143-26-000050
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$38.1M	2024-03-30	2026-05-20	10-K	0000313143-26-000050
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$273.1M	2023-04-01	2025-05-21	10-K	0000313143-25-000025
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$191.3M	2023-04-01	2025-05-21	10-K	0000313143-25-000025
36	current assets	us-gaap:AssetsCurrent	\$935.0M	2025-03-29	2026-05-20	10-K	0000313143-26-000050
37	current liabilities	us-gaap:LiabilitiesCurrent	\$578.1M	2025-03-29	2026-05-20	10-K	0000313143-26-000050
38	assets	us-gaap:Assets	\$2.2B	2024-03-30	2025-05-21	10-K	0000313143-25-000025
39	assets	us-gaap:Assets	\$1.9B	2023-04-01	2024-05-20	10-K	0000313143-24-000020
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	45,445,983	2026-05-15	2026-05-20	10-K	0000313143-26-000050
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	48,036,996	2025-05-16	2025-05-21	10-K	0000313143-25-000025